203 related articles for article (PubMed ID: 26146959)
1. KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; BinEssa H; Alanazi AA; Alzahrani AS; Akhtar M; Assiri AM; Meyer BF; Shi Y
Lab Invest; 2015 Nov; 95(11):1269-77. PubMed ID: 26146959
[TBL] [Abstract][Full Text] [Related]
2. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
3. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
[TBL] [Abstract][Full Text] [Related]
4. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
5. Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.
Macià A; Vaquero M; Gou-Fàbregas M; Castelblanco E; Valdivielso JM; Anerillas C; Mauricio D; Matias-Guiu X; Ribera J; Encinas M
Cell Death Differ; 2014 Feb; 21(2):333-43. PubMed ID: 24270409
[TBL] [Abstract][Full Text] [Related]
6. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor.
Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY
Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057
[TBL] [Abstract][Full Text] [Related]
7. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
8. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
[TBL] [Abstract][Full Text] [Related]
9. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
11. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
12. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
[TBL] [Abstract][Full Text] [Related]
13. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
Milewska M; Romano D; Herrero A; Guerriero ML; Birtwistle M; Quehenberger F; Hatzl S; Kholodenko BN; Segatto O; Kolch W; Zebisch A
PLoS One; 2015; 10(6):e0129859. PubMed ID: 26065894
[TBL] [Abstract][Full Text] [Related]
15. Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.
Chiappetta G; Fabien N; Picone A; Califano D; Monaco C; de Franciscis V; Vecchio G; Santelli G
Oncol Res; 1996; 8(2):85-93. PubMed ID: 8859779
[TBL] [Abstract][Full Text] [Related]
16. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
18. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
19. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
Macià A; Gallel P; Vaquero M; Gou-Fabregas M; Santacana M; Maliszewska A; Robledo M; Gardiner JR; Basson MA; Matias-Guiu X; Encinas M
Oncogene; 2012 Aug; 31(35):3961-72. PubMed ID: 22158037
[TBL] [Abstract][Full Text] [Related]
20. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.
Lee SJ; Lee MH; Kim DW; Lee S; Huang S; Ryu MJ; Kim YK; Kim SJ; Kim SJ; Hwang JH; Oh S; Cho H; Kim JM; Lim DS; Jo YS; Shong M
PLoS One; 2011 Jan; 6(1):e16180. PubMed ID: 21249150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
